Display options
Cite
Revillion F, Lhotellier V, Hornez L, et al. Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int J Biol Markers. 2008;23(1):10-17doi: 10.5301/JBM.2008.2066.
Revillion, F., Lhotellier, V., Hornez, L., Leroy, A., Baranzelli, M. C., Giard, S., Bonneterre, J., & Peyrat, J. P. (2008). Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. The International journal of biological markers, 23(1), 10-17. https://doi.org/10.5301/JBM.2008.2066
Revillion, F, et al. "Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion." The International journal of biological markers vol. 23,1 (2008): 10-17. doi: https://doi.org/10.5301/JBM.2008.2066
Revillion F, Lhotellier V, Hornez L, Leroy A, Baranzelli MC, Giard S, Bonneterre J, Peyrat JP. Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int J Biol Markers. 2008 Jan - Mar;23(1):10-17. doi: 10.5301/JBM.2008.2066. PMID: 28207102.
Copy Download .nbib Format: NLM
Share it on

Int J Biol Markers. 2008 Jan - Mar;23(1):10-17. doi: 10.5301/JBM.2008.2066.

Real-time reverse-transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion.

The International journal of biological markers

F Revillion, V Lhotellier, L Hornez, A Leroy, M C Baranzelli, S Giard, J Bonneterre, J-P Peyrat

Affiliations

  1. Laboratoire dOncologie Molculaire Humaine, Centre de Lutte Contre le Cancer Oscar Lambret, Lille - F.

PMID: 28207102 DOI: 10.5301/JBM.2008.2066

Abstract

At the Centre Oscar Lambret, the anticancer centre of the North of France, sentinel lymph node (SLN) procedures are routinely performed for localized (T0-T1, N0, M0) breast carcinoma without any previous treatment, in order to prevent the deleterious effects of axillary lymph node dissection. The present study was undertaken to assess if the expression in the tumor of a panel of 19 genes would allow to predict histological SLN involvement. We looked at cytokeratin 19 (CK19), mucin-1 (MUC1), mammaglobin (MGB1), cyclin D1 (CCND1), the four members of the HER/ErbB growth factor receptor family (EGFR, HER2-4), insulin-like growth factor-1 receptor (IGF-1R), estradiol receptors (ERalpha, ERbeta), progesterone receptor (PR), vascular endothelial growth factors (VEGF, VEGF-C), urokinase-like plasminogen activator (uPA), matrix metalloproteinases 2 and 9 (MMP2, MMP9), ets-related transcription factor ERM, and E-cadherin (CDH1). Their expression was quantified by real-time RT-PCR in 134 breast cancer samples and the relationships with SLN metastases were analyzed. A slight increase (35-40%) in CK19 and HER3 expression was observed in the tumors of patients with SLN metastases compared to those of patients without metastases, even if neither CK19 expression nor HER3 expression allowed to distinguish patients with micrometastases from patients with macrometastases. We conclude that the tumoral expression of biological parameters involved in cell proliferation or playing a critical role in the metastatic process, including tumor invasion and angiogenesis, is not strongly associated with SLN metastases.

Publication Types